Novo Nordisk Ignored Internal Warnings on Wegovy Launch Preparedness, Leading to Supply Shortages and Pricing Criticism

Novo Nordisk allegedly ignored internal warnings about its preparedness to launch Wegovy, a key obesity drug. Executives were warned about supply and insurance coverage issues, but the company launched the drug too quickly, leading to shortages and high costs. Wegovy's launch was plagued by supply shortages and high costs, while rival Eli Lilly's Zepbound gained momentum. Novo is undergoing a leadership shake-up, including the dismissal of CEO Lars Fruergaard Jorgensen, amid concerns over its competitiveness in the weight-loss market.